USP美国药典-NF 1503 英文 Quality Attributes of Synthetic Peptide Drug Substances.docx

USP美国药典-NF 1503 英文 Quality Attributes of Synthetic Peptide Drug Substances.docx

此“医疗卫生”领域文档为创作者个人分享资料,不作为权威性指导和指引,仅供参考
  1. 1、本文档共23页,可阅读全部内容。
  2. 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多

Printedon:TueAug302022,10:01:32am

Printedby:AlbertZhao

Status:CurrentlyOfficialon30-Aug-2022

OfficialDate:Officialasof01-Aug-2021

DocumentType:GENERALCHAPTER

DocId:GUID-36322BA3-3F12-4A80-9020-156D7EEBFB89_2_en-US

DOI:/10.31003/USPNF_M12935_02_01

DOIRef:r9xxs

?2022USPC

Addthefollowing:

▲〈1503〉QUALITYATTRIBUTESOFSYNTHETICPEPTIDEDRUGSUBSTANCES

INTRODUCTION

PEPTIDEDEFINITION

MANUFACTURINGMETHODS

RAWMATERIALS

PEPTIDEGENERALCHARACTERISTICSANDSPECIFICATION

ColorandAppearance

Identification

Bioassays

AssayandPeptideContent

Impurities

MicrobiologicalContamination

BacterialEndotoxins

SpecificTests

INTRODUCTION

Thepharmaceuticalindustry’sinterestinpeptidesasdrugcandidates—basedontheirpotency,enormousfunctionaldiversity,highdegreeofspecificity,andgenerallackoftoxicity—hasexistedsincetheirgeneralstructurewasfirstelucidatedmorethan100yearsago.Theearlydevelopmentofsyntheticpeptidesfortherapeuticusewas,however,challengedbythehighcostsofproduction,theirinherentlyshortin-vivohalf-lives,thelackofsensitiveanddiscriminatinganalyticalmethodsforintermediates,andtherelativelycomplexmanufacturingmethods,whicharenowreferredtoas“solutionpeptidesynthesis”or“liquid-phasepeptidesynthesis”(LPPS).

Theintroductionofsolid-phasepeptidesynthesis(SPPS)wasakeyfactorinfacilitatingtheexpansionofpeptideresearchandmadetheproductionofpeptideswithsequenceslongerthan20aminoacidsfeasible.Also,inrecentyears,newformulationsandconjugationstrategieshaveresultedinalternativeroutesofadministrationandlongerhalf-livesforpeptidetherapeutics,whichhavefacilitatedpatientcompliance.Asaresult,morepeptidedrugshavebeenapprovedandareinclinicaldevelopment.Inspiteofthesesuccesses—orperhapsbecauseofthem—somechallengesinpeptidemanufacturingremain,especiallywiththeincreasing

您可能关注的文档

文档评论(0)

Antonio周正义 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档